Cytogam^® helps significantly reduce the incidence of CMV disease in kidney, lung, liver, pancreas, heart, and heart-lung transplantation^1,^2,^3,^4,⁵

Clinical studies have shown a 50% reduction in primary CMV disease in renal transplant patients given Cytogam^®³ and a 56% reduction in serious CMV disease5 in liver transplant patients given Cytogam^®. Cytogam^® prophylaxis was associated with increased survival in liver transplant recipients.⁶

Cytogam^®: Provides an additional layer of protection without the toxicity

Transplant patients who received a combination of Cytogam^® and antiviral medication such as ganciclovir* or valganciclovir* had the following results:

Heart recipients: Significantly greater 3-year survival and 3-year freedom from rejection²
Heart recipients: 28% reduction in relative risk for CMV infection⁷
Heart-lung recipients: Fewer deaths from obliterative bronchiolitis²
Liver recipients: Viral hepatitis was reduced from the expected level of ~ 60% to 6.6%⁴

* Note to users of Valcyte^® (valganciclovir), the prodrug of ganciclovir: After oral administration, the diasteromers of Valcyte are rapidly converted to ganciclovir by intestinal and hepatic esterases. Valcyte is a registered trademark of Roche Pharmaceuticals.

1. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049-54.

2. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001;72:1647-52.

3. Snydman DR, Werner BG, Tilney NL, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc. 1991;23:1357-60.

4. Ham JM, Shelden SL, Godkin RR, Posner MP, Fisher RA. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant Proc. 1995;27(5)Suppl 1:31-3.

5. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993;119:984-91.

6. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, and Rohrer R. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant. 1997;11:432-7.

7. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation. 2006;82:398-405.

© 2008 CSL Behring

Important Safety Information

Cytogam^® is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart.

Cytogam^® is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations and in persons with selective immunoglobulin A deficiency who have known antibodies to IgA.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients predisposed to acute renal failure include patients with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentrations available and the minimum rate of infusion practicable.

Increases in serum creatinine and blood urea nitrogen (BUN) have been observed as soon as one to two days following IGIV infusion. Progression to oliguria or anuria requiring dialysis has been observed.

Cytogam^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Minor reactions, such as flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing, were the most frequent adverse reactions observed during the clinical trials for Cytogam^®.

For more information about Cytogam^®, please see the full prescribing information.

Cytogam^® is a registered trademark of CSL Behring AG.

Cytogam® helps significantly reduce the incidence of CMV disease in kidney, lung, liver, pancreas, heart, and heart-lung transplantation1,2,3,4,5

Cytogam®: Provides an additional layer of protection without the toxicity

© 2008 CSL Behring

Important Safety Information

Cytogam^® helps significantly reduce the incidence of CMV disease in kidney, lung, liver, pancreas, heart, and heart-lung transplantation^1,^2,^3,^4,⁵

Cytogam^®: Provides an additional layer of protection without the toxicity